Scholarlink

<p>The resistance of doxorubicin (DOX), the first-line chemotherapeutic drug for osteosarcoma (OS), stands as a pivotal obstacle in the effective treatment of OS. Alterations in mitochondrial dynamics and thereby affecting reactive oxygen species (ROS) accumulation play critical roles in DOX-induced cell death. However, the novel targets and pharmacological agents combating DOX resistance in OS via mitochondrial homeostasis and DOX-induced cell death manipulation is poorly understood. Herein, we showed that the C/EBPα/GREM1/p-ERK signaling pathway sensitizes OS to DOX by promoting mitochondrial fission and causing ROS-induced apoptosis. C/EBPα agonist ICCB280 and ERK pathway inhibitor PD98059 both played a DOX sensitivity augmentation role in OS in vitro and in vivo. The combined application of these two agents synergistically amplifies the cytotoxic impact of DOX, potentially overcoming DOX resistance and offering innovative therapeutic strategies for treating DOX-resistant OS.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

C/EBP alpha agonist ICCB280 overcomes doxorubicin resistance in osteosarcoma through mitochondrial dynamics-dependent GREM1-MAPK activation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月25日

查看全文
  • Yuchen Han,
  • Hui Li,
  • Chunyuan Xue,
  • Lu Pan,
  • Li Liu,
  • Hui Chen,
  • Zhendong Wang,
  • Fengkun Ji,
  • Yinglong Zhang,
  • Xiaofeng Kang,
  • Ying Lu,
  • Yimeng Du,
  • Jianxiong Li,
  • Wenchao Li

摘要

The resistance of doxorubicin (DOX), the first-line chemotherapeutic drug for osteosarcoma (OS), stands as a pivotal obstacle in the effective treatment of OS. Alterations in mitochondrial dynamics and thereby affecting reactive oxygen species (ROS) accumulation play critical roles in DOX-induced cell death. However, the novel targets and pharmacological agents combating DOX resistance in OS via mitochondrial homeostasis and DOX-induced cell death manipulation is poorly understood. Herein, we showed that the C/EBPα/GREM1/p-ERK signaling pathway sensitizes OS to DOX by promoting mitochondrial fission and causing ROS-induced apoptosis. C/EBPα agonist ICCB280 and ERK pathway inhibitor PD98059 both played a DOX sensitivity augmentation role in OS in vitro and in vivo. The combined application of these two agents synergistically amplifies the cytotoxic impact of DOX, potentially overcoming DOX resistance and offering innovative therapeutic strategies for treating DOX-resistant OS.